E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of EPE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EPE Relative Value
Base Case
Not Available
E
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
1 894.7
Median 5Y
107.3
Industry
7.6
Forward
1 295.6
vs History
vs Industry
Median 3Y
-483.5
Median 5Y
-11.2
Industry
22.1
Forward
-323.1
vs History
vs Industry
Median 3Y
-481.5
Median 5Y
-12.9
Industry
21.9
vs History
vs Industry
Median 3Y
-435.5
Median 5Y
-16.4
Industry
23.4
vs History
vs Industry
Median 3Y
-4 952.1
Median 5Y
-12.3
Industry
2.5
vs History
vs Industry
Median 3Y
1 896.4
Median 5Y
90.4
Industry
7.5
Forward
1 296.7
vs History
vs Industry
Median 3Y
2 509.9
Median 5Y
1 699.7
Industry
9.3
vs History
vs Industry
Median 3Y
-526.5
Median 5Y
-8.8
Industry
4.2
vs History
vs Industry
Median 3Y
-512.5
Median 5Y
-8.8
Industry
4
vs History
vs Industry
Median 3Y
-481.9
Median 5Y
-10.6
Industry
5.9
vs History
vs Industry
Median 3Y
-481.2
Median 5Y
-10.5
Industry
3.9
vs History
vs Industry
Median 3Y
876
Median 5Y
44.9
Industry
4.5

Multiples Across Competitors

EPE Competitors Multiples
Epizyme Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.3 -499.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
317.9B USD 5.7 62.5 15.5 23.9
US
Amgen Inc
NASDAQ:AMGN
141.7B USD 4.4 33.6 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 4.1 928.1 10.3 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.9B USD 9.9 -219.3 21.6 22.7
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 5.7 16.9 15.3 17
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.3 -109.3 -79.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.3B USD 14.9 -94.2 -223.6 -157.1
P/S Multiple
Revenue Growth P/S to Growth
US
E
Epizyme Inc
F:EPE
Average P/S: 3 467 701.5
1 847
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
34%
0.3
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.9
96%
0.2
P/E Multiple
Earnings Growth P/E to Growth
US
E
Epizyme Inc
F:EPE
Average P/E: 214.6
Negative Multiple: -471.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.5
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.6
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
928.1
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -219.3
48%
N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -94.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBITDA: 16.4
Negative Multiple: -513.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
43%
0.5
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -223.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBIT: 21.5
Negative Multiple: -499.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
45%
0.5
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -157.1 N/A N/A

See Also

Discover More
Back to Top